BR112023020685A2 - Acopladores de cd70 baseados em darpin - Google Patents

Acopladores de cd70 baseados em darpin

Info

Publication number
BR112023020685A2
BR112023020685A2 BR112023020685A BR112023020685A BR112023020685A2 BR 112023020685 A2 BR112023020685 A2 BR 112023020685A2 BR 112023020685 A BR112023020685 A BR 112023020685A BR 112023020685 A BR112023020685 A BR 112023020685A BR 112023020685 A2 BR112023020685 A2 BR 112023020685A2
Authority
BR
Brazil
Prior art keywords
nucleic acids
binding proteins
darpin
human
pharmaceutical compositions
Prior art date
Application number
BR112023020685A
Other languages
English (en)
Portuguese (pt)
Inventor
Bernd Schlereth
Christian Reichen
Nina Reschke
Original Assignee
Molecular Partners Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Partners Ag filed Critical Molecular Partners Ag
Publication of BR112023020685A2 publication Critical patent/BR112023020685A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Lock And Its Accessories (AREA)
  • Ignition Installations For Internal Combustion Engines (AREA)
  • Valve Device For Special Equipments (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112023020685A 2021-04-09 2022-04-07 Acopladores de cd70 baseados em darpin BR112023020685A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163173186P 2021-04-09 2021-04-09
US202163172973P 2021-04-09 2021-04-09
US202163265181P 2021-12-09 2021-12-09
PCT/IB2022/053275 WO2022215032A1 (en) 2021-04-09 2022-04-07 Novel darpin based cd70 engagers

Publications (1)

Publication Number Publication Date
BR112023020685A2 true BR112023020685A2 (pt) 2023-12-12

Family

ID=81386901

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023020685A BR112023020685A2 (pt) 2021-04-09 2022-04-07 Acopladores de cd70 baseados em darpin

Country Status (9)

Country Link
US (1) US20250074994A1 (cg-RX-API-DMAC7.html)
EP (1) EP4319883A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024513559A (cg-RX-API-DMAC7.html)
KR (1) KR20230169182A (cg-RX-API-DMAC7.html)
AU (1) AU2022252985A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023020685A2 (cg-RX-API-DMAC7.html)
CA (1) CA3214020A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023011978A (cg-RX-API-DMAC7.html)
WO (1) WO2022215032A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL298168A (en) 2020-05-14 2023-01-01 Molecular Partners Ag Multispecific proteins
WO2022190016A1 (en) 2021-03-09 2022-09-15 Molecular Partners Ag Novel darpin based multi-specific t-cell engagers
WO2024251628A1 (en) * 2023-06-06 2024-12-12 Molecular Partners Ag Recombinant cd16a binding proteins and their use
JP2026524079A (ja) 2023-06-06 2026-07-17 モレキュラー パートナーズ アクチェンゲゼルシャフト 組換えcd2結合タンパク質及びその使用
WO2025181039A1 (en) 2024-03-01 2025-09-04 Molecular Partners Ag Therapeutic combinations comprising a multi-specific t cell engager

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100150950A1 (en) * 2006-12-14 2010-06-17 Medarex, Inc. Human antibodies that bind cd70 and uses thereof
EP3974453A3 (en) * 2010-11-16 2022-08-03 Amgen Inc. Agents and methods for treating diseases that correlate with bcma expression
EP3514169B1 (en) * 2010-11-26 2024-03-06 Molecular Partners AG Designed repeat proteins binding to serum albumin
JP2016531920A (ja) * 2013-09-05 2016-10-13 アデュロ・バイオテック・ホールディングス・ヨーロッパ・ベスローテン・フエンノートシャップAduro Biotech Holdings, Europe B.V. Cd70結合ペプチドおよびそれに関連する方法、プロセスおよび用途
US9458211B1 (en) * 2015-04-02 2016-10-04 Molecular Partners Ag Recombinant proteins that simultaneously bind HGF, VEGF-A and serum albumin, comprising ankyrin repeat domains
US11291721B2 (en) * 2016-03-21 2022-04-05 Marengo Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
MX2020008183A (es) * 2018-02-01 2020-09-22 Pfizer Anticuerpos especificos para cd70 y sus usos.
TW202010757A (zh) * 2018-04-11 2020-03-16 美商英伊布里克斯公司 具有經受限cd3結合的多重特異性多肽構築體以及相關方法及用途
JP2022535564A (ja) * 2019-06-04 2022-08-09 モレキュラー パートナーズ アクチェンゲゼルシャフト 多選択性タンパク質
EP3980452A1 (en) * 2019-06-04 2022-04-13 Molecular Partners AG Recombinant 4-1bb binding proteins and their use
WO2022190016A1 (en) * 2021-03-09 2022-09-15 Molecular Partners Ag Novel darpin based multi-specific t-cell engagers

Also Published As

Publication number Publication date
KR20230169182A (ko) 2023-12-15
US20250074994A1 (en) 2025-03-06
WO2022215032A1 (en) 2022-10-13
JP2024513559A (ja) 2024-03-26
EP4319883A1 (en) 2024-02-14
MX2023011978A (es) 2023-11-17
CA3214020A1 (en) 2022-10-13
AU2022252985A1 (en) 2023-11-16

Similar Documents

Publication Publication Date Title
BR112022023049A2 (pt) Proteínas multiespecíficas
BR112023018293A2 (pt) Acopladores de célula t multiespecíficos à base de darpin
MX2023011978A (es) Captadores de cd70 novedosos basados en darpin.
MX2021014601A (es) Proteinas recombinantes de union a fap y su uso.
BR112022011456A2 (pt) Proteínas recombinantes de ligação a complexo de peptídeo-mhc e geração e uso das mesmas
MX2023007067A (es) Proteinas recombinantes de union a cd3 y su uso.
PE20220505A1 (es) Moleculas de union a tigit y pd-1/tigit
CO2022003582A2 (es) Métodos para el tratamiento de la oftalmopatía tiroidea
Au et al. TGF-βI regulates cell migration through pluripotent transcription factor OCT4 in endometriosis
Ke et al. Nickel compounds induce histone ubiquitination by inhibiting histone deubiquitinating enzyme activity
BR112017020986A2 (pt) proteínas de ligação recombinantes e seu uso
Yuanping et al. HMGB1-activated fibroblasts promote breast cancer cells metastasis via RAGE/aerobic glycolysis.
SA522432139B1 (ar) بروتينات ربط متعددة الخصوصية لمعالجة السرطان
CR20220618A (es) Nuevas proteinas de unión a repeticiones de anquirina y sus usos
Nakao et al. Fibroblast growth factors 7 and 10 are involved in ameloblastoma proliferation via the mitogen-activated protein kinase pathway
TW201606083A (zh) 製備誘導多能幹細胞之方法及其應用
AR063493A1 (es) Nuevos anticuerpos anti notch 3 y su uso para la deteccion y el diagnostico de enfermedades
BR112021024237A2 (pt) Domínio de repetição de anquirina projetado com estabilidade aprimorada
BR112021024997A2 (pt) Anticorpos, polinucleotídeo, vetor de expressão, célula hospedeira, composição farmacêutica, métodos e uso
Prusinski Fernung et al. A preliminary study: human fibroid Stro-1+/CD44+ stem cells isolated from uterine fibroids demonstrate decreased DNA repair and genomic integrity compared to adjacent myometrial Stro-1+/CD44+ cells
BR112022018491A2 (pt) Marcadores de superfície celular recombinante
Behera et al. Abrus precatorius agglutinin-derived peptides induce ROS-dependent mitochondrial apoptosis through JNK and Akt/P38/P53 pathways in HeLa cells
Neary et al. Calcium-activated, phospholipid-dependent protein kinase and protein substrates in primary cultures of astrocytes
WO2021116470A3 (en) Recombinant peptide-mhc complex binding proteins and their generation and use
Nakajima et al. Immunohistochemical demonstration of 14‐3‐3 sigma protein in normal human tissues and lung cancers, and the preponderance of its strong expression in epithelial cells of squamous cell lineage

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]